As populations age, Alzheimer’s disease (AD) is becoming a growing crisis in the United States and around the world. It’s estimated that more than 15 million Americans will suffer from AD by 2050. This disease and other neurodegenerative disorders steal our memories, our identity, and our independence, placing a profound burden on caregivers, families, and communities. Despite decades of work, there are still no effective cures. 

The Alzheimer’s Center at Temple (ACT) is committed to confronting this challenge through cutting-edge basic, translational, and clinical research. Our goal is to better understand the biology of AD, its risk factors, and the complex conditions that drive brain aging and neurodegenerative disorders, including traumatic brain injury (TBI). We focus on areas such as neuroinflammation, oxidative stress, and lipid and protein balance in the brain — key contributors to synaptic dysfunction and cognitive decline. 

Supported by NIH, DoD, and philanthropic partners like the Scott Richards North Star Charitable Foundation, ACT brings together expert neuroscientists, clinicians, and researchers. Together, we are developing promising diagnostic biomarkers and therapies, translating them from bench to bedside. 

A critical part of our mission is to attract, foster and mentor excellent faculty and trainees. These next generation of researchers and clinicians are harnessing the power of state-of-the-art neuroscience tools along with Temple University’s commitment to compassionate care. 

Our vision is for ACT to be a leader in collaborative, translational research that not only advances science but also improves the wellbeing of the whole community. 

Silvia Fossati, PhD 
Director, Alzheimer’s Center at Temple (ACT)